Photo of Dennis Bourdette, M.D., FANA, FAAN

Dennis Bourdette M.D., FANA, FAAN

    • Professor of Neurology School of Medicine
    • Dr.Roy and Eulalia Swank family research professor Neurology School of Medicine
    • Director OHSU Multiple Sclerosis Center School of Medicine
    • Neuroscience Graduate Program School of Medicine
    • Jungers Center for Neurosciences Research

Dr. Bourdette is chair of the Department of Neurology, Roy and Eulalia Swank family research professor, executive director of the OHSU Multiple Sclerosis Center and co-director of the VA MS Center of Excellence-West. He directs a team dedicated to curing and treating diseases such as multiple sclerosis, Alzheimer’s, Parkinson’s, stroke, and ALS.

He is nationally recognized for his important discoveries in the field of multiple sclerosis and oversees an annual research budget of over $2 million. His team has attracted grants from the National Institutes of Health, Department of Veterans Affairs, National MS Society, Nancy Davis Foundation for Multiple Sclerosis, to name a few. He and his colleagues have received international attention for their development of a TCR peptide vaccine called Neurovax for the treatment of multiple sclerosis and a new therapy called VG1000 being developed with a local biotechnology company, Virogenomics. Dr. Bourdette received his medical degree at the University of California at Davis, joined OHSU in 1984 as a resident in the Department of Neurology.

Read more

Education

  • M.D., University of California-Davis Medical School 1978
  • Residency:

    • Medicine – Santa Clara Valley Medical Center, San Jose
    • Neurology – Oregon Health & Science University
  • Fellowship:

    • Neuroimmunology – Veterans Affairs Medical Center, Portland

Memberships and associations

  • American Board of Neurology and Psychiatry, 1985

Publications

  • "IX. Neurological and vascular disorders. A. General" Journal of rehabilitation R&D  1991
  • "Cognitive Impairment and Community Integration Outcomes in Individuals Living With Multiple Sclerosis" Archives of Physical Medicine and Rehabilitation November 1 2015
  • "Veterans Health Administration Multiple Sclerosis Centers of Excellence" Journal of rehabilitation R&D  2006
  • "Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis" Neurology December 26 2001
  • "A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis" Multiple Sclerosis October 2005
  • "Human myelin basic protein (MBP) epitopes recognized by mouse MBP-selected T cell lines from multiple sclerosis patients" Journal of Neuroimmunology  1994
  • "Genetic inactivation of the p66 isoform of ShcA is neuroprotective in a murine model of multiple sclerosis" European Journal of Neuroscience February 2012
  • "Autoantibodies and Sjogren's Syndrome in Multiple Sclerosis, a Reappraisal" PLoS One June 12 2013
  • "Some effects of multiple sclerosis on speech perception in noise" Journal of rehabilitation R&D  2006
  • "Specificity of human T cell clones reactive to immunodominant epitopes of myelin basic protein" Journal of Neuroscience Research  1991
  • "Immunotherapy and multiple sclerosis" Neurology May 2010
  • "Monomeric Recombinant TCR Ligand Reduces Relapse Rate and Severity of Experimental Autoimmune Encephalomyelitis in SJL/J Mice through Cytokine Switch" Journal of Immunology April 1 2004
  • "Exploring educational needs of multiple sclerosis care providers" Journal of rehabilitation R&D  2006
  • "Phenotype and function of hematopoietic-derived cells in the CNS of SCID mouse-Lewis rat bone marrow chimeras" Journal of Neuroscience Research September 15 1996
  • "Oxidative stress inhibits axonal transport" Molecular Neurodegeneration  2012
  • "Effects of vaccination with T cell receptor peptides" Immunology and Cell Biology  1998
  • "Response to comment on letter for" Multiple Sclerosis  2014
  • "Recombinant T-cell receptor ligand (RTL) for treatment of multiple sclerosis" Autoimmune Diseases  2012
  • "Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis" Journal of Neuroimmunology  1992
  • "Lipoic acid" Endocrine, Metabolic and Immune Disorders - Drug Targets June 2008
  • "The radiologically isolated syndrome" Current Neurology and Neuroscience Reports October 2011
  • "Cognitive impairment and MS" Current Neurology and Neuroscience Reports October 2011
  • "Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis" Journal of Neuroimmunology October 2002
  • "Rudimentary TCR signaling triggers default IL-10 secretion by human TH1 cells" Journal of Immunology October 15 2001
  • "A randomized pilot study of naturopathic medicine in multiple sclerosis" Journal of Alternative and Complementary Medicine June 1 2008
  • "Herpes zoster ophthalmicus and delayed ipsilateral cerebral infarction" Neurology  1983
  • "Suppressor cell regulation of encephalitogenic T cell lines" Cellular Immunology April 1 1990
  • "New disease-modifying therapies and new challenges for MS" Current Neurology and Neuroscience Reports October 2012
  • "Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis" Immunology January 2008
  • "Lipoic acid reduces inflammation in a mouse focal cortical experimental autoimmune encephalomyelitis model" Journal of Neuroimmunology December 15 2015

Additional information

Edit profile